Rodrigo Cristofoletti
Overview
Explore the profile of Rodrigo Cristofoletti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yamamoto P, Vozmediano V, Cristofoletti R, Jiang J, Schmittgen T, de Gaitani C, et al.
Br J Clin Pharmacol
. 2024 Jun;
90(9):2223-2235.
PMID: 38852609
Aims: A population-based pharmacokinetic (PK) modeling approach (PopPK) was used to investigate the impact of Roux-en-Y gastric bypass (RYGB) on the PK of (R)- and (S)-carvedilol. We aimed to optimize...
12.
Eltanameli B, Pineiro-Llanes J, Cristofoletti R
Expert Opin Drug Metab Toxicol
. 2024 Jun;
20(6):439-458.
PMID: 38850058
Introduction: Recent years have witnessed remarkable progress in the development of cell-based in vitro models aimed at predicting drug permeability, particularly focusing on replicating the barrier properties of the blood-brain...
13.
Coutinho A, Cristofoletti R, Wu F, Shoyaib A, Dressman J, Polli J
Pharm Res
. 2024 May;
41(6):1121-1138.
PMID: 38720034
Purpose: The goal was to assess, for lipophilic drugs, the impact of logP on human volume of distribution at steady-state (VD) predictions, including intermediate fut and Kp values, from six...
14.
Patel R, Cristofoletti R, Wu F, Shoyaib A, Polli J
J Pharm Sci
. 2024 Apr;
113(8):2361-2373.
PMID: 38614321
It is desirable to predict positive food effect of oral formulations due to food mediated dissolution enhancement of lipophilic drugs. The objective was to assess the ability of in vitro...
15.
Kowthavarapu V, Charbe N, Gupta C, Iakovleva T, Stillhart C, Parrott N, et al.
AAPS J
. 2024 Apr;
26(3):44.
PMID: 38575716
Mechanistic modeling of in vitro experiments using metabolic enzyme systems enables the extrapolation of metabolic clearance for in vitro-in vivo predictions. This is particularly important for successful clearance predictions using...
16.
Pineiro-Llanes J, da Silva L, Huang J, Cristofoletti R
J Vis Exp
. 2024 Apr;
(205).
PMID: 38557663
Extracellular matrix (ECM) plays a critical role in cell behavior and development. Organoids generated from human induced pluripotent stem cells (hiPSCs) are in the spotlight of many research areas. However,...
17.
Klose M, Cristofoletti R, De Miranda Silva C, Mangal N, Turgeon J, Michaud V, et al.
Eur J Pharm Sci
. 2024 Jan;
194:106689.
PMID: 38171419
Oxycodone is one of the most commonly used opioids to treat moderate to severe pain. It is metabolized mainly by CYP3A4 and CYP2D6, while only a small fraction of the...
18.
Plano D, Rudolph N, Saal C, Abrahamsson B, Cristofoletti R, Kambayashi A, et al.
J Pharm Sci
. 2023 Nov;
113(2):386-395.
PMID: 37951471
A Biopharmaceutics Classification System (BCS)-based biowaiver monograph is presented for isavuconazonium sulfate. A BCS-based biowaiver is a regulatory option to substitute appropriate in vitro data for in vivo bioequivalence studies....
19.
Caleffi-Marchesini E, Herling A, Macente J, Bonan R, de Freitas Lima P, Moreno R, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Nov;
13(2):208-221.
PMID: 37916262
Physiologically-based biopharmaceutics modeling (PBBM) has potential to accelerate the development of new drug and formulations. An important application of PBBM is for special populations such as pediatrics that have pharmacokinetics...
20.
Rodriguez-Vera L, Yin X, Almoslem M, Romahn K, Cicali B, Lukacova V, et al.
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896246
Regulatory agencies worldwide expect that clinical pharmacokinetic drug-drug interactions (DDIs) between an investigational new drug and other drugs should be conducted during drug development as part of an adequate assessment...